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The area around Cys-192 and Cys-193 is thought o be a functionally important part of the cc-subunit of 
the acetylcholine r ceptor. We have synthesized peptide ct182-198 of the a-chain of the Torpedo californica 
acetylcholine r ceptor and investigated the binding to the peptide of a-bungarotoxin, cobratoxin and anti- 
bodies raised against acetylcholine r ceptor. The results howed that the synthetic peptide ~~182-198 con- 
tains a second toxin-binding region and also binds a considerable fraction of anti-receptor antibodies. We 
also report here the toxin-binding activity of synthetic peptide a1255148 of the human acetylcholine receptor 
which has been previously localized as a toxin-binding region in the a-chain of the Torpedo receptor. 
Acetylcholine receptor Toxin-binding region Synthetic peptide 
Antigenic site 
Cobratoxin a-Bungaro toxin 
1. INTRODUCTION 
The nicotine acetylcholine receptor (AChR)+ 
from Torpedo electroplaque is a multi-subunit 
glycoprotein that mediates ion flux across the cell 
membrane in response to binding of acetylcholine 
[l-4]. The receptor complex is composed of 4 dif- 
ferent subunits existing in a stoichiometry (~2pys. 
The primary structures of all 4 subunits have been 
elucidated from cDNA sequences [5-71. Several 
studies have shown that the a-subunit contains the 
acetylcholine-binding site [8-lo]. The regulatory 
activity of this site(s) is inhibited by binding to an 
cu-neurotoxin [e.g. cr-bungarotoxin (BgTX) or 
cobratoxin (CbTX)] from snake venom [l l] and, 
therefore, these toxins serve as very specific, high- 
affinity probes for the acetylcholine-binding site 
P21. 
Based upon sequence analysis, structural 
topology and site-directed mutagenesis, it has been 
* To whom correspondence should be addressed 
proposed that the area around the invariant cys- 
teine residues 128 and 142, and/or cysteine 
residues 192-193 is/are essential for binding to 
acetylcholine and toxin to receptor [5-7,141. More 
direct evidence was recently obtained [ 131 by show- 
ing that a synthetic peptide corresponding to 
residues 125-147, with a disulfide bond between 
Cys-128 and Cys-142, of the Torpedo receptor 
possessed high binding activity to both 1251- 
labelled BgTX and [3H]acetylcholine. 
This paper reports the synthesis and binding ac- 
tivity of a peptide corresponding to residues 
182-198 of the Torpedo a-subunit, to BgTX and 
CbTX as well as to anti-AChR antibodies. The 
toxin-binding activity of this peptide is compared 
to the Torpedo loop peptide aT125-147 [13] and 
to the human loop peptide ~~125-148 correspond- 
ing to residue 125-148 of the human a-subunit, 
also synthesized here for the first time. These 
studies have shown that the synthetic peptide 
aT182-198 possessed high binding activity to ‘251- 
labelled BgTX and CbTX. This region also bound 
considerable amounts of anti-AChR antibodies. 
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2. MATERIALS AND METHODS 
2.1. Isolation of Torpedo AChR receptor 
The preparation of AChR from the electric 
organ tissue of Torpedo californica (Pacific Bio- 
Marine Laboratories) was carried out as described 
by Froehner and Rafto [15]. Receptor was 
solubilized from membranes in buffer containing 
1% Triton X-100 and then purified by affinity 
chromatography on CbTx (Baja naja siameensis)- 
Sepharose CL4B. Binding activity was determined 
by DE81 filter assay [ 161. Purity and subunit com- 
position of AChR were checked by polyacrylamide 
gel electrophoresis in SDS [17]. 
2.2. Synthesis and purification of the peptides 
The peptides (~T182-198 and ryH125-148 (fig.1) 
were synthesized by the Merrifield solid-phase 
method [ 181. The side chain protecting groups used 
on the Na-t-butyloxy amino acids (Vega 
Biochemicals) were: y- and fl-benzyl esters for 
glutamic and aspartic acids, guan-NO2 for 
arginine, O-benzyl for serine and threonine, 
2-chloro-Cbz for lysine e-NH2, 2,6-dichlorobenzyl 
for tyrosine hydroxyl, 4-methylbenzyl for cysteine 
SH and dinitrophenyl for the imidazole group of 
histidine. The 1-hydroxybenzotriazole/DCC cou- 
pling procedure [19] was used to incorporate the 
Asn, Gin, Arg, and His residue, while the coupling 
of all other amino acids was performed by sym- 
metric anhydrides [20]. A 6 molar excess of the t- 
Boc-amino acid and 3 equivalents of DCC were 
used with respect o the starting load on the resin. 
The t-Boc group was removed with 40% 
trifluoroacetic acid in CHK12 (v/v). The 
dinitrophenyl protecting group on histidine was 
removed from the completed peptide by thiolysis 
with benzenethiol. Cleavage of the peptide from 
the resin was performed by anhydrous HF contain- 
ing anisole (30 min, -20°C). 
The peptides were purified by gel filtration on 
Sephadex G-25 (Pharmacia) in 0.05 M tri- 
ethylamine to obtain the monomeric fractions [13] 
followed by ion-exchange chromatography on 
DEAE-Sephacel [13]. Homogeneity of the prod- 
ucts was monitored by high-voltage paper elec- 
trophoresis 1211. Amino acid analysis of acid 
hydrolysates was performed on a Beckman 6300 
amino acid analyzer. For the determination of 
tryptophan cvTl82-198, the peptide was- hydro- 
lysed with 3 M p-toluenesulfonic acid [22]. Cys- 
teine was determined on the analyzer as cysteic 
acid after oxidation of the hydrolysates with per- 
formic acid. 
2.3. Adsorbent-binding studies 
Proteins (BgTX, CbTX, immune IgG) and pep- 
tides were labelled with i2’I (Amersham) using the 
chloramine-T method [23]. Protein-linked 12’1 was 
assayed by precipitation with 10% (w/v) 
trichloroacetic acid. Mouse antibodies against 
TAChR elicited by immunization of mice (Swiss 
Webster) in complete Freund’s adjuvant at 3 week- 
ly intervals. The antisera used here were 80 day 
bleed from mice. The IgG fractions of anti-AChR 
antisera were prepared as described [26]. 
Coupling of the peptides to CNBr-activated 
Sepharose CL4B [24] was carried out under the 
optimum conditions [25]. Adsorbents of BgTX 
and CbTX were prepared by the same method. Ad- 
sorbents of unrelated proteins and unrelated syn- 
thetic peptides [25,26] were used as controls for 
non-specific binding. AChR was coupled in a 
similar manner to that used for other proteins, ex- 
cept that the coupling buffer was 0.2 M NaHC03, 
pH 9.5, containing 0.1 M NaCl and 0.2% Triton 
X-100. The binding of either ‘251-labelled BgTX or 
CbTX to AChR to peptide adsorbents or, con- 
Fig. 1. Covalent structures of the synthetic peptides 
studied here. Peptides cYT182-198 and aHI148, 
which were synthesized in the present work, were both 
started on glycine-resin for ease of synthesis. Therefore, 
in these two peptides, the C-terminal glycine is not part 
of the natural sequence in Torpedo or human AChR. 
The synthesis and activity of peptide aT!25-147 have 
been reported [ 131. 
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versely, of labelled peptides to BgTX or CbTX ad- 
sorbents was determined by a quantitative solid- 
phase radiometric binding assay [25,27]. 
The solid-phase radiometric binding assay was 
also used for studying antibody binding activity of 
the peptide [25]. Peptide-Sepharose conjugates 
were incubated with 12SI-labelled immune IgG 
from mouse anti-AChR antisera and antibody 
binding was determined as in [25]. Adsorbents of 
unrelated proteins and peptides were as controls. 
Also, the binding to AChR peptide of antibodies 
against unrelated proteins served as additional 
controls. Antibody binding was determined by a 
double-antibody assay [28] using 1251-labelled rab- 
bit and mouse IgG to monitor the binding of 
unlabelled mouse anti-AChR antibodies. 
In all binding experiments, non-specific binding 
was determined by titrating, under identical condi- 
tions, equivalent volumes of uncoupled Sepharose 
and Sepharose coupled to unrelated proteins and 
synthetic peptides. 
3. RESULTS 
3.1. Purification and characterization of the 
synthetic peptides 
After purification, the synthetic peptides were 
homogeneous by peptide mapping. In amino acid 
analysis, the synthetic peptides had compositions 
which were in agreement with those expected from 
their sequence (fig.1). Their amino acid composi- 
tions (with the values expected from the sequence 
in parentheses) were: peptide cuT182-198, Asp, 
1.09 (1); Thr, 1.92 (2); Pro, 2.06 (2); Gly, 0.98 (1); 
Val, 0.95 (1); Tyr, 2.85 (3); His, 0.85 (1); Lys, 0.88 
(1); Arg, 0.94 (1); Trp, 1.98 (2); l/2 Cys (deter- 
mined as cysteic acid), 2.05 (2); peptide ~H125- 
148, Asp, 2.07 (2); Thr, 1.90 (2); Ser, 1.80 (2); Glu, 
3.02 (3); Pro, 0.96 (1); Gly, 1.05 (1); Val, 0.98 (1); 
Met, 0.86 (1); Ile, 1.92 (2); Leu, 1.02 (1); Tyr, 1 .OO 
(1); Phe, 2.13 (2); His, 1.01 (1); Lys, 2.06 (2); l/2 
Cys (determined as cysteic acid), 1.95 (2). The syn- 
thesis, characterization and activity of peptide 
c~T125-147 have been reported [13]. 
Peptide c~T182-198 was confirmed to be a 
monomer by gel filtration on a calibrated column 
of Sephadex G-25 in 0.05 M triethylamine with an 
apparent M, of 2000. Reaction of the peptide with 
5,5 ‘-dithiobis(2-nitrobenzoic acid) in 5 M guani- 
dine HCI at pH 8.0 as described by Habeeb [29] 
70 
revealed the presence of two free thiol groups. This 
was confirmed by reaction of the peptide with a 50 
molar excess of ICHzCONHz. After removal of 
excess reagent by gel filtration on Sephadex G- 15, 
amino acid analysis of acid hydrolysates of the 
derivative gave 1.9 mol S-carboxymethylcysteine/ 
mol peptide. Thus, the thiol groups on the vicinal 
cysteine residues 192 and 193 were free and did not 
form a disulfide bond. On the other hand, the 
monomeric peptide aH125-148 did not react with 
the reagents unless it was first reduced by NaBH4. 
After reduction, peptide (~H125-148 showed the 
presence of 2.0 thiol groups, clearly indicating that 
the monomer exists as a loop with a disulfide bond 
between Cys-128 and Cys-142 (fig.1). It should 
also be noted that the peptide cuT125-147 is a 
monomer with a disulfide bond between Cys-128 
and Cys-142 [13]. 
3.2. Binding of 1251-labelled peptides to toxin 
adsorben ts 
Both synthetic regions, 125-148 and 182-198, 
were bound to toxin adsorbents (fig.2). However, 





Fig.2. Binding of ‘Z51-labelled peptides (rT182-198 and 
cuH125-148 to CbTX adsorbent. A fixed volume (15 ~1 
of a 1: 1 suspension) of CbTX adsorbent was titrated 
with different amounts of radioiodinated peptides (5 x 
104, lo’, 2 X lo5 and 3 x lo5 cpm). The specific activities 
of the labelled peptides were: peptide (~T182-198, 
1.63 pCi/nmol; peptide cuH125-148, 5.45 pCi/nmol. 
(-) Binding to CbTX of: (0) peptide ~uT182-198; 
(m) peptide c~H125-148. (---) Binding of the two 
peptides to: (A) adsorbent of bovine serum albumin 
and, (0) adsorbents of human hemoglobin synthetic 
peptide a45-56 [26]. 
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under these conditions ‘*‘I-labelled peptides 
~T125-147 or aH125-148 showed lower binding 
activity than ‘*‘I-labelled aT182-198. Specificity 
of this binding was confirmed by the finding that 
unrelated 1251-labelled proteins and peptides did 
not bind to toxin adsorbents. In general labelled 
peptides bound very poorly to toxin (fig.2) 
because, in all likelihood, several amino -acid side 
chains (tryptophan, tyrosine, histidine, methio- 
nine, cysteine and cystine), some of which may be 
essential contact residues, can potentially undergo 
oxidation by chloramine-T [30] during radio- 
iodination resulting in derivatives with very poor 
binding activity. More definitive results were ob- 
tained by binding labelled toxins onto peptide ad- 
sorbents, therefore, this method was used. 
thetic peptides was first determined by titrating a 
fixed amount of 12sI-labelled BgTX with varying 
amounts of peptide adsorbents. The binding values 
in the plateau region are summarized in table 1 and 
show that both peptides bound amounts of BgTX 
that were considerable, being 40-74% relative to 
the amount bound by AChR: non-specific binding 
to unrelated proteins and peptides was only 3-5% 
relative to AChR. 
Binding studies were also carried out on the ab- 
sorbents of AChR and of the two peptides 
aT182-198 and @H125-128 synthesized here as 
well as the adsorbent of the previously reported 
[13] peptide of Torpedo (~T125-147, using a fixed 
amount of adsorbent suspension and increasing 
amounts of 1251-labelled CbTX and BgTX. In titra- 
tion with CbTX (fig.3), the binding curves of the 
3.3. Binding of ‘251-labelled toxins to peptide 
adsorbents 
The binding of BgTX to adsorbents of the syn- 
Table 1 
Binding of BgTX to synthetic peptides aHl25-148 and 
cuTl82-198 
Sepharose adsorbent ‘251-labelled BgTX 
bound (cpm) 
AChR 36800 f 889 
Peptide (~Tl92-148 27278 f 1217 
Peptide ruHl25--148 14670 + 256 
Bovine serum albumin 1334 f 66 
Hemoglobin A 1595 + 10 
Myoglobin 1848 & 101 
Hemoglobin peptide a45-56a 1493 f 59 
‘Nonsense’ peptideb 1361 + 77 
a This represents an adsorbent, used here as a control, of 
a synthetic peptide corresponding to residues 45-56 of 
the a-chain of human hemoglobin A. The synthesis 
and characterization of this peptide have been reported 
I261 
b ‘Nonsense’ peptide is a synthetic peptide that does not 
correspond to any part of AChR, and its adsorbent is 
used here as a control. The synthesis and 
characterization of this peptide have been reported [25] 
I I 1 1 I 
lo 20 30 
12sl-CbTX added (cpm x 10-j 
Binding to protein and peptide adsorbents was measured 
by a quantitative radiometric binding assay, using a 
fixed amount of ‘2SI-labelled BgTX (10’ cpm) and 
increasing amounts of adsorbents. The results below 
summarize the mean plateau binding values of triplicate 
Fig.3. Binding of ‘251-labelled CbTX to receptor, 
synthetic peptides and controls. Increasing amounts of 
labelled CbTX were added to a fixed volume (25 ~1 of 
1: 1 suspension) of each adsorbent. (-) Titration 
curves of the toxin with adsorbents of (A) AChR, (0) 
peptide (uT182-198, (m) peptide cuHl25-148, (0) 
peptide (rTl25-147. (---) Binding of the toxin to 
control adsorbents of (A) bovine serum albumin, ( l ) 
sperm whale myoglobin, (0) human hemoglobin 
synthetic peptide ~45-56, (A) human adult hemoglobin 
and (0) nonsense peptide [25]. The specific activity of 
experiments the labelled toxin was 18.95 &i/nmol. 
71 
Volume 199, number 1 FEBS LETTERS April 1986 
human and Torpedo peptides aH 12% 148 and 
cuT125-147 (representing equivalent structural 
regions on the a-chain of the respective species) 
were identical. On the other hand, the binding 
curve of the Torpedo peptide lrTl82- 198 was con- 
siderably higher. The binding curve of AChR 
under the same condition is shown in fig.3. 
Similar titration studies were carried out with a 
fixed amount of each adsorbent and increasing 
amounts of 1Z51-labelled BgTX (fig.4). In titration 
with BgTX, AChR showed, as expected, the 
highest binding. The highest peptide binding ac- 
tivity was exhibited by peptide ruTl82-198 fol- 
lowed by peptides cuHl25--148 and ~~Tl25-147, in 
that order. Peptide rrT182-198 showed, on the ad- 
sorbent, apparent affinities with BgTX and CbTX 
of 6.6 x IO-* and 1 x 10e7 M, respectively, while 
the corresponding values for peptide aHl25-148 
I 1 r A I 
fir 60 
'0 t / 1 
I / t 
I. J 
lo 20 30 
‘P61-B~fX addad (epm xlr’l 
Fig.4. Binding curves of ‘2SI-labeIled BgTX to AChR, 
synthetic peptides and controls. Fixed volumes of 
adsorbents (25 pl of 1: 1 suspension) were titrated with 
increasing amounts of *2sI-labelled BgTX. (-) 
Titration curves of the toxin with adsorbents of (A) 
AChR, (0) peptide crT182-198, (u) cuH125-148, (0) 
oTi25-147. (---) Binding behavior to control 
adsorbents of (A) bovine serum albumin, (=I sperm 
whale myoglobin, (of human hemoglobin synthetic 
peptide a45-56, (A) human adult hemoglobin and (0) 
nonsense peptide. The specific activity of the labelled 
l-6 -214 + 45 -4k 10 
Nonsense peptide - 144 f 32 373 4 50 
(A} Results of the direct antibody assay in which i2’I- 
labelled mouse anti-AChR antibody (2.5 x 10’ cpm) was 
incubated (4”C, 18 h) with varying amounts of peptide 
or protein adsorbents; (B) results obtained by the 
double-antibody assay. An aliquot (20 ~1) of unlabelled 
mouse anti-AChR antisera (prediluted 1: 500, v/v) is 
incubated (4”C, 18 h) with increasing amounts of 
adsorbent. This is followed, after washing, with an 
aliquot (2.5 x 10’ cpm) of ‘251-labeiled rabbit anti- 
mouse IgG. After washing (5 times) all the tubes on the 
centrifuge, they were counted on a gamma counter. AI1 
dilutions, solvents and washing solutions were 1% fetal 
bovine serum in PBS. The results, which summarize 
plateau binding values (obtained with 100~1 of 1: I 
suspension of adsorbents), have been corrected for non- 
specific binding [(A) 1693 cpm; (B) 1570 cpml by an 
toxin was 18.2 pCi/nmol. equal volume of uncoupled Sepharose 
were 1.5 x lo-’ and 2.2 x IO-’ M. Labelled toxins 
did not bind to adsorbents of unrelated proteins 
and peptides, thus confirming the specificity of the 
previousiy discussed binding results. 
3.4. Antibody-binding studies 
Quantitative radioimmunoadsorbent itrations 
were carried out both with ‘251-Iabelled anti-AChR 
antibodies and by a double-antibody assay. In a 
given titration, a fixed amount of antibody and in- 
creasing amounts of adsorbents were used, The 
results in table 2 summarize the mean plateau 
binding values by both assays and show that pep- 
tide cuTl82-198 binds a considerable fraction of 
anti-AChR antibodies. The antibody binding to 
unrelated control proteins and peptides is negligi- 
ble (table 2). 
Table 2 
Binding of anti-AChR antibody to synthetic peptide 
(rT182-198 of the AChR a-chain of Torpedo californica 
and to unrelated controls 
Sepharose 
adsorbent 
Antibody bound (cpm) by: 
(A) Direct (3) Double- 
antibody antibody 
AChR 79707 + 1270 125125 +- 2240 
(rT182-198 17261 k 1011 28007 + 1120 
Bovine serum albumin 236 + 18 118 rfr 27 
Myoglobin 98 2 20 368 rt 72 
Myoglobin peptide 
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4. DISCUSSION 
Previously, it was reported [13] that a synthetic 
peptide corresponding to sequence 125-147 of the 
a-subunit of the Torpedo AChR had high binding 
activity toward BgTX. We report here that the 
17-residue synthetic peptide corresponding to the 
sequence 182-198 of the a-chain of the Torpedo 
AChR (cuT182-198) has very high binding activity 
toward both CbTX and BgTX. 
As a result of site-directed mutagenesis ex- 
periments [14], the residues Cys-192 and Cys-193 
of the a-subunit have been proposed to play a role 
in receptor binding. However, since it is difficult to 
separate the effect of replacing a residue from that 
of any attending conformational readjustments 
which result from that replacement, it remains 
usually uncertain whether the effect of a substitu- 
tion on the binding activity of a protein directly 
implicates the residue that has been altered as a 
‘contact’ residue or whether it may simply be the 
by-product of conformational changes. 
The results presented here provide direct 
evidence that the receptor has a second toxin- 
binding region which resides within the a-chain 
fragment 182-198. Peptide 125-148 of thecu-chain 
of the human AChR was synthesized in order to 
confirm further the universal activity of this 
binding region in two different species. In this 
region of the a-chain, the human sequence differs 
from the Torpedo sequence at positions 139 and 
143. The residues Gln-139 and Thr-143 in Torpedo 
a-chain are replaced in the human protein by 
glutamic acid and serine, respectively. The sub- 
stitution of threonine by serine is conservative and 
probably will not adversely affect the binding ac- 
tivity of this region. On the other hand, substitu- 
tion of glutamine by glutamic acid will result in a 
drastic charge alteration which would more likely 
be disruptive to the binding activity if this is an 
essential contact residue. Also, it should be noted 
that in the synthetic peptide c~T125-147, Met-144 
was replaced by norleucine [13]. 
The present results show that the human syn- 
thetic peptide aH125-148 possesses considerable 
binding activity with both BgTX and CbTX, which 
is comparable to that of the Torpedo synthetic 
peptide aT125-147. However, in the binding to 
BgTX, the human peptide shows higher affinities. 
Thus, it may be concluded that residue 139 on the 
peptides has little or no involvement in the binding 
of the toxin to AChR. But this replacement and/or 
the replacements at position 143 and 144 may 
modulate the region’s affinity for the toxin. 
The results reported here also show that this 
second toxin-binding region, residues a182-198, is 
also recognized as a major antigenic site by an- 
tibodies raised against native AChR. A con- 
siderable fraction of anti-AChR antibodies is 
bound specifically by this region of the LY chain. 
Whether antibodies against this region play a role 
in the autoimmune disease, myasthenia gravis, is 
now under investigation. It is not implied that this 
antigenic site includes all of the residues 182-198, 
but rather it resides within these residues. 
Thus, it has been shown unequivocally that the 
a-chain of AChR has a second toxin-binding 
region which has been localized to fall within, but 
may not necessarily include all of the residue 
182-198. This region may not be independent of 
the region within residue 121-148. It is not possi- 
ble to distinguish at present whether these two 
regions represent distinct binding sites on the (Y- 
chain for toxin or whether they are two ‘faces’ 
within a single binding site, the binding energy of 
each face being sufficient to form a complex with 
one face of a toxin-binding site. The results also do 
not exclude the possibility that regions and/or 
residues from other parts of the a-chain may con- 
tribute to the toxin-binding site(s). Determination 
of the three-dimensional structure of AChR or its 
a-chain should help to clarify this question. 
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